• HOME
  • DCVAX ® TECHNOLOGY
    • About DCVax®
    • Dendritic Cell Immunotherapy
    • Patient Stories & Physician Comments
  • PRODUCT CANDIDATES
    • DCVax® – L
    • DCVax® – Direct
    • DCVax® – Prostate
  • CLINICAL TRIALS
    • DCVax® – L Phase III for GBM Brain Cancer
    • DCVax® – Direct Phase I/II for All Types of Inoperable Solid Tumor Cancers
  • INVESTORS & MEDIA
    • Press Releases
    • SEC Filings
    • Webcasts
    • Board Committee Charters
    • Code of Conduct
    • Notice of Proposed Settlement
    • Related-Party Transaction Policy
    • Corporate Governance Guidelines
  • ABOUT US
    • Overview
    • Company Management
    • Publications
    • Related Links
    • Contact Us
      • General Inquiries
      • Patient Inquiries

Webcast: Dr. Marnix Bosch’s Presentation on DCVax® from ASCO 2018

Follow us On: 
  • DCVAX® TECHNOLOGY
    • About DCVax®
    • Dendritic Cell Immunotherapy
    • Patient Stories & Physician Comments
  • PRODUCT CANDIDATES
    • DCVax® – L
    • DCVax® – Direct
    • DCVax® – Prostate
  • CLINICAL TRIALS
    • Pipeline
    • DCVax® – L Phase III
    • DCVax® – Direct Phase I/II
  • INVESTORS & MEDIA
    • Contacts
    • SEC Filings
    • Stock Information
    • Press Releases
    • Webcasts
  • ABOUT US
    • Overview
    • Company Management
    • Publications
    • Related Links
    • Contact Us

© 2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
Phone: 240-497-9024

  • Forward-looking Statement
  • Legal Disclaimer
  • Privacy Policy